Pharmafile Logo

Early Pipeline Case Study

International Childhood Cancer Day Infographic

International Childhood Cancer Day 2019

The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...

Cuttsy + Cuttsy

- PMLiVE

AZ says dropping MedImmune will help ‘streamline’ its R&D

Will also drop other candidates that haven’t hit the mark

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE decision puts NHS in vanguard for new use

- PMLiVE

Immuno-oncology in 2019: the rapid evolution continues

Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?

- PMLiVE

FCB Health’s Neon attracts new managing director

Mardene Miller will lead the agency with co-managing director Kevin McHale

- PMLiVE

Lucid Group acquires digital and creative agency Bluedog

The move comes as the group celebrates its 12-year anniversary

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

- PMLiVE

Cancer drugs and China sustain AZ’s return to growth

Tagrisso set to become biggest seller

Lucid Group brings creative and digital magic to the mix with the acquisition of Bluedog

Lucid Group is delighted to announce its first acquisition, welcoming colleagues from creative and digital consultancy Bluedog into its magic kingdom.Over the last twelve years, Lucid Group has become well...

Lucid Group Communications Limited

Lucid Group acquires creative and digital agency Bluedog

Lucid Group is delighted to announce its first acquisition, welcoming colleagues from creative and digital consultancy Bluedog into its magic kingdom.

Lucid Group Communications Limited

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links